Safety of Options to “Boost” (Enhancing Insulin Infusion Rates) and “Ease-Off” (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis
Authors' conclusion
Boost and Ease-off allow users to engage safely with CamAPS FX to manage their glucose levels during periods of more-than-usual and less-than-usual insulin needs.
Study context
- Population
- Users of the CamAPS FX hybrid closed-loop system
- Participants
- 7,464 users
- Exposure
- Boost and Ease-off periods vs no Boost and no Ease-off periods
- Outcome
- Time below 70 mg/dL (Boost) and time above 180 mg/dL (Ease-off)
Methodological details12-month period
- 12-month period
Main finding
As reported in the abstract
Boost
0.0%
median · IQR 0.0–0.5%
No Boost
2.1%
median · IQR 1.2–3.4%
Ease-off
15
± 14 · %
No Ease-off
25
± 12 · %
Observational data: associations, not effects.
Further findings
| Outcome | Boost | Ease-off |
|---|---|---|
| Starting glucoseAbove range for Boost, within range for Ease-off | mean 229 ± 51 mg/dL | mean 114 ± 29 mg/dL |
Usage
- Boost used more frequently than Ease-off, but for a shorter duration per use
Safety
- Episodes of severe hypoglycaemia or DKA attributed to Boost or Ease-off use
- 0
Original publication
Safety of Options to “Boost” (Enhancing Insulin Infusion Rates) and “Ease-Off” (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis. Diabetes Technol Ther. Published 9 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →